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Abstract 
  
Recent studies find that pterostilbene (PTS) exhibits more favorable drug 
properties and similar chemopreventive effects to its structural analogue resveratrol 
(RSV).  However, few studies describe the activity of PTS in prostate cancer (PCa).  
Here, we conducted cell count experiments to assess the effects of PTS on metastatic PCa 
cell viability and to compare the potency of PTS to RSV in this respect.  We also 
performed experiments to assess the effects of PTS on the androgen receptor (AR) and 
AR-mediated events.  We used qPCR to measure the mRNA levels of the androgen-
responsive gene (ARG), prostate-specific antigen (PSA), and Western blots to assess the 
expression and subcellular localization of the AR protein in LNCaP cells.  We found that 
PTS inhibited cell viability more potently than RSV in androgen-dependent LNCaP and 
androgen-independent PC-3 cells.  These inhibitory effects were time and dose-
dependent and suggest that PTS may provide chemopreventive effects at multiple stages 
of disease.  PTS also inhibited androgen-induced PSA mRNA levels in LNCaP cells.  
However, this inhibitory effect could not be fully attributed to changes in the androgen-
induced expression or nuclear translocation of AR protein.  Therefore, further 
investigation is required to elucidate PTS’s effects on AR-mediated events and to assess 
the clinical applicability of PTS in PCa.  
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Introduction 
Prostate cancer (PCa) is the second-leading cause of cancer-related death among 
American men and the majority of PCa deaths result from advanced disease [1].  
Advanced disease refers to PCa that has metastasized beyond the prostate and its adjacent 
tissues, including the seminal vesicles, bladder neck, and pelvic lymph nodes [2].  At 
present, there is no cure for advanced PCa and clinical management of the disease 
remains problematic [2-4].  Tumors in advanced disease can quickly develop resistance 
to multiple treatments, and as a result, men who begin advanced PCa therapy experience 
a median progression-free survival of just 12-18 months [3].  The median overall survival 
from the start of treatment is less than three years [5].  Therefore, advanced PCa 
represents a significant concern to men’s health in the United States due to the high 
incidence of disease and its recalcitrance to current therapeutic modalities.  
Endocrine-based therapies provide greater clinical benefit to men with advanced 
PCa than traditional chemotherapeutics, and first-line treatments are agents that impair 
androgen receptor (AR) activity [4-6].  The AR is a transcription factor that forms 
complexes with co-regulatory and mediator proteins to regulate the transcription of 
androgen-responsive genes (ARGs) [2,3].  This activity is required for the normal 
development and function of the prostate gland [2].  However, dysregulation of AR 
signaling can lead to abnormal gene expression and contribute to the initiation and 
progression of PCa [2].  Recent studies indicate that this aberrant signaling plays a 
significant role in all stages of disease, including castration-resistant PCa (CRPC) [2,3].  
Thus, inhibition of AR activity has become the therapeutic mainstay in the treatment of 
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advanced disease [5].  
Androgen deprivation therapy (ADT) employs LHRH (luteinizing-hormone-
releasing hormone) antagonists to block the production of testicular androgens and 
second-line anti-androgens to competitively inhibit the AR [4-6].  This approach provides 
a clinical benefit to ~80% of men with advanced disease, stalling cancer progression, 
decreasing the size of the prostate and metastatic tumors, and alleviating symptoms such 
as bone pain [4-6].  However, ADT is not a curative intervention and disease regression 
is generally short-lived [4-6].  Subcellular changes to the structure and microenvironment 
of the AR mediate resistance to ADT agents and as a result, all men with advanced PCa 
ultimately progress despite treatment [2,3,7,8].  This establishes a clear need for new 
therapeutic agents in the field of advanced PCa. 
Resveratrol (RSV) is a natural polyphenol that displays promising 
chemopreventive activity in preclinical studies of advanced PCa [9-12].  Experiments 
performed in vitro find that RSV inhibits cell growth and induces apoptosis in a number 
of metastatic PCa cell lines, including the androgen-dependent LNCaP and androgen-
independent PC-3 cell lines [13,14].  This chemopreventive activity has been attributed, 
at least in part, to RSV’s ability to inhibit the androgen-induced expression and function 
of the AR [15-18].  However, unlike conventional ADT agents, RSV does not inhibit AR 
activity through ligand deprivation, competitive antagonism, or disruption of AR nuclear 
translocation [15-18].  Instead, RSV appears to act through a unique mechanism of action 
that has yet to be fully described.  This may be significant as agents demonstrating novel 
methods of AR inhibition have recently improved the treatment of metastatic disease and 
emphasized new therapeutic targets in the AR signaling pathway [19-21].   
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Despite these preclinical results, RSV is not a viable candidate for clinical use in 
PCa at this time [22].  Pharmacokinetic studies indicate that RSV has a short half-life and 
limited bioavailability in human subjects [23-26].  RSV is particularly prone to phase II 
metabolism and is rapidly conjugated to glucuronide and sulfate groups by cells of the 
liver and small intestine [23].  Thus, recent efforts were made to identify compounds that 
exhibit similar pharmacologic activity to RSV with more favorable drug properties [27-
29].  Pterostilbene (PTS), a natural analogue of RSV, may fulfill these criteria and 
therefore hold greater potential to elicit chemopreventive effects in human subjects 
[27,28].   
 
Figure 1.  Chemical structures of PTS and RSV. 
 
The chemical structures of PTS and RSV differ by just two methoxy groups (Fig. 
1).  However, this subtle variation affords PTS a number of pharmacokinetic advantages 
[29].  PTS exhibits greater lipophilicity, a longer half-life (3-7x), and greater 
bioavailability (3-4x) than RSV in animal models [22,29,30].  This corresponds to other 
findings that methylated polyphenols are more efficiently absorbed by the intestines and 
less vulnerable to hepatic conjugation than their unmethylated counterparts [29].  In the 
first clinical trial involving PTS, the drug was well tolerated at the highest 
 
 
 
 
 
 
Pterostilbene (PTS) Resveratrol (RSV) 
(B) (A) 
H3CO 
  OCH3 
 OH 
 OH 
 HO 
OH 
5  
administered dose of 250mg/day [31].  Thus, all available evidence suggests that PTS 
possesses a superior pharmacokinetic profile to its structural analogue, RSV.  
Recently, PTS was found to elicit similar, and at times more potent, anti-
carcinogenic effects to RSV in preclinical models of colon cancer, hepatocellular 
carcinoma, and malignant melanoma [9,28].  However, few studies have investigated the 
chemopreventive effects of PTS in PCa.  Chakraborty et al. found that PTS inhibited cell 
proliferation and induced apoptosis in androgen-independent PC-3 cells [32].  The 
authors also reported that PTS inhibited molecular targets associated with cell 
proliferation and survival (PKB, Bcl-2, and MMP-9) and induced factors associated with 
pro-apoptotic events (Bax and caspases) in these cells [32].  In another study, Wang et al. 
found that PTS triggered cell cycle arrest in androgen-dependent LNCaP cells, 
upregulating cyclin-dependent kinase inhibitors, CDKN1A and CDKN1B [33].  
However, there is still much to learn about the chemopreventive effects of PTS in PCa 
and how these effects compare to those demonstrated by RSV.    
In the present study, we conducted cell count experiments to assess the effects of 
PTS on metastatic PCa cell viability and to compare the potency of PTS to RSV in this 
respect.  We found that PTS, like RSV, inhibited the viability of androgen-dependent 
LNCaP and androgen-independent PC-3 cells in a time and dose-dependent manner.  PTS 
was significantly more potent than RSV in producing these effects.  We also performed 
qPCR and Western blot experiments to assess the effects of PTS on the androgen receptor 
(AR) and AR-mediated events in LNCaP cells.  We found that PTS inhibited androgen-
induced mRNA levels of the ARG, prostate-specific antigen (PSA).  However, this 
inhibitory effect could not be fully attributed to changes in the androgen-induced 
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expression or nuclear translocation of AR protein.  Therefore, further investigation is 
required to better elucidate the effects of PTS on AR-mediated events and to assess the 
clinical applicability of PTS in PCa.  
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Materials and Methods 
Reagents:   
Culture media RPMI 1640 (1x) with L-glutamine and Ham’s F-12 (1x) with L-
glutamine were purchased from Mediatech, Inc. (Manassas, VA).  Phenol Red Free 
RPMI 1640 (1x) with L-glutamine was purchased from Gibco by Life Technologies 
(Carlsbad, CA).  Media were stored at 4°C.  Antibiotic-Antimycotic (100x) (Gibco by 
Life Technologies) was also stored at 4°C.  Premium Fetal Bovine Serum (FBS) and 
Charcoal/dextran treated FBS were purchased from Atlanta Biological (Oakwood, GA) 
and stored at -20°C.  Trypsin (.25%, 2.21mM EDTA) (Mediatech, Inc.) was also stored at 
-20°C.  LNCaP and PC-3 cells were purchased from the American Type Culture 
Collection (ATCC) (Manassas, VA).  Pterostilbene was purchased from Sigma-Aldrich 
(St. Louis, MO) and dissolved in DMSO (Sigma-Aldrich) to create a 100mM stock 
solution.  Resveratrol (Sigma-Aldrich) was dissolved in ethanol (Biotechnology Grade 
Anhydrous-Alcohol, IBI Scientific, Peosta, IA) to create a 200mM stock solution.  
Synthetic androgen R1881 (Sigma-Aldrich) was dissolved in ethanol to create a 10mM 
stock solution.  Solutions were stored in the dark at -30°C.  The qPCR primer pairs for 
PSA (5’- TCCCCCTGCCCATGTCCCAG -3’ and 5’- GTGCAGCACCTGCAGAGGGG 
-3’) and GAPDH (5’- GTCAAGGCTGAGAACGGGAA -3’ and 5’- 
AAATGAGCCCCAGCCTTCTC -3’) were purchased from Invitrogen (Carlsbad, CA) 
and diluted with reaction-grade double distilled (RGDD) water to create 100µM stock 
solutions.  Solutions were stored in the dark at -30°C.  AR Antibody (N-20): sc-816 was 
purchased from Santa Cruz Biotechnology (Dallas, TX) and stored at 4°C.  Cytoplasmic 
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Extraction (CE) buffer was prepared with 10mM HEPES, 60mM KCl, 1mM EDTA, 
1mM DTT, 1mM PMSF (Sigma-Aldrich), and 0.075% (v/v) NP40 (Novex by Life 
Technologies).  RIPA buffer was prepared with 50mM Tris-Cl, 150mM NaCl, 1mM 
PMSF, 0.50% DOC, 0.10% SDS, 1mM DTT (Sigma-Aldrich), and 1% (v/v) NP40 
(Novex by Life Technologies).  Buffers were stored at 4°C. 
 
Cell Cultures: 
LNCaP cells were cultured in Media A (RPMI 1640 with L-glutamine, 10% 
Premium FBS, 1% Antibiotic-Antimycotic).  In some experiments, Media A was 
replaced by Media B (Phenol Red Free RPMI 1640 with L-glutamine, 10% 
Charcoal/dextran treated FBS, 1% Antibiotic-Antimycotic).  PC-3 cells were cultured in 
Media C (Ham’s F-12 with L-glutamine, 10% Premium FBS, 1% Antibiotic-
Antimycotic).  Cells were kept in an incubator at 37°C in the presence of 5% CO2. 
 
Cell Count Methods: 
LNCaP cells in Media B were distributed evenly into six 24-well plates (Becton 
Dickinson Labware, Lincoln Park, NJ) by adding 1mL of a single cell suspension to the 
wells of each plate in a 6 x 3 arrangement.  Plates were then stored in an incubator for 12 
hours (37°C, 5% CO2).  After 12 hours, three plates were treated with PTS and/or R1881 
as follows: Row 1: “Control” (0µM PTS, 0nM R1881), Row 2: “Androgen Control” 
(0µM PTS, 10nM R1881), Row 3: 5µM PTS, 10nM R1881, Row 4: 10µM PTS, 10nM 
R1881, Row 5: 15µM PTS, 10nM R1881, Row 6: 20µM PTS, 10nM R1881.  Remaining 
plates were treated with RSV and/or R1881 as follows: Row 1: “Control” (0µM RSV, 
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0nM R1881), Row 2: “Androgen Control” (0µM RSV, 10nM R1881), Row 3: 10µM 
RSV, 10nM R1881, Row 4: 20µM RSV, 10nM R1881, Row 5: 50µM RSV, 10nM 
R1881, Row 6: 100µM RSV, 10nM R1881.  Following treatment, plates were returned to 
the incubator.   
After 24 hours, one PTS-treated plate and one RSV-treated plate were removed 
from the incubator for cell counting.  Media and detached cells were aspirated from each 
well and replaced by 100µL of trypsin (20°C).  After several minutes, the remaining cells 
were suspended in 500µL of Media A (20°C) and distributed into 1.5mL eppendorf tubes 
(on ice).  The Countess Automated Cell Counter (Invitrogen) was used to determine the 
number of viable cells in a 5µL sample drawn from each tube.  This procedure was then 
used to evaluate cell viability after 48 and 72-hour treatments using the remaining two 
pairs of plates.  
Similar methods were used for cell count experiments with PC-3 cells.  PC-3 cells 
were cultured in Media C and distributed into six 24-well plates by adding 1mL of a cell 
suspension to the wells of each plate in a 5 x 3 arrangement.  Plates were then stored in 
an incubator for 12 hours.  After 12 hours, three plates were treated with PTS as follows: 
Row 1: “Control” (0µM PTS), Row 2: 5µM PTS, Row 3: 10µM PTS, Row 4: 15µM PTS, 
Row 5: 20µM PTS.  Remaining plates were treated with RSV as follows: Row 1: 
“Control” (0µM RSV), Row 2: 10µM RSV, Row 3: 20µM RSV, Row 4: 50µM RSV, 
Row 5: 100µM RSV.  Following treatment, cells were collected and counted as described 
previously except that Media C was used in place of Media A. 
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qPCR Methods: 
LNCaP cells were suspended in Media A and distributed evenly into six 10mL 
plates (Chemglass Life Sciences, Vineland, NJ).  Plates were stored in an incubator for 
24 hours (37°C, 5% CO2).  After 24 hours, Media A was replaced by Media B and plates 
were returned to the incubator for 6 hours.  After 6 hours, plates were treated as follows: 
Plate 1: “Control” (0µM PTS, 0nM R1881), Plate 2: “Androgen Control” (0µM PTS, 
10nM R1881), Plate 3: 5µM PTS, 10nM R1881, Plate 4: 10µM PTS, 10nM R1881, Plate 
5: 15µM PTS, 10nM R1881, Plate 6: 20µM PTS, 10nM R1881.  After 24 hours, total 
RNA was isolated from each plate using the RNeasy Plus Micro Kit (Qiagen, Venlo, 
Limburg, Netherlands), according to the manufacturer’s instructions.  RNA was 
quantified using the NanoDrop 2000c UV-Vis Spectrophotometer and then reverse 
transcribed using Random 9-mer Primers (Stratagene, La Jolla, CA) and the SuperScript 
II Reverse Transcriptase Kit (Invitrogen), according to the manufacturer’s instructions.  
Resulting cDNA was diluted (5x) in RGDD and stored overnight at -30°C. cDNA 
samples were prepared for qPCR using the reagents and protocol of the SYBR Advantage 
qPCR Premix (Clontech Laboratories, Inc., Mountain View, CA), and primers pairs for 
PSA and GAPDH (Invitrogen).  Samples were distributed in triplicate into a 96-well 
qPCR plate (Applied biosystems, Life technologies) and loaded into the ABI PRISM 
7000 Sequence Detection System.  Using the ABI Software, PSA was labeled as a target 
gene and GAPDH as an endogenous control.  The threshold was set automatically and 
cycling conditions were entered as follows: Initial Denaturation (1 Rep., 95°C, :30), 
Two-Step PCR (40 Rep., Denaturation: 95°C, :05; Annealing/Extension: 60°C, :37).  The 
ABI software used the fluorescence data to calculate one relative quantification (RQ) 
11  
value per triplicate.  RQ values (2-ddCt) from three separate experiments were then used 
for statistical analysis.    
 
Western Blot Methods: 
LNCaP cells were suspended in Media A and distributed evenly into eighteen 
10mL plates (one plate to source each nuclear, cytoplasmic, and whole cell lysate for six 
treatment groups).  Plates were stored in an incubator for 24 hours (37°C, 5% CO2).  
After 24 hours, Media A was replaced by Media B and plates were returned to the 
incubator for 6 hours.  After 6 hours, plates were treated with different concentrations of 
PTS and/or 10nM R1881 for 24 hours.  After 24 hours, one plate from each treatment 
group was removed from the incubator.  Cells were collected by scraping and transferred 
to 1.5mL eppendorf tubes.  Cell pellets were isolated and whole cell lysates were 
obtained using RIPA buffer.  Cells from the remaining two plates in each treatment group 
were combined into 1.5mL eppendorf tubes.  Cell pellets were isolated and CE buffer 
was used to separate the contents of each tube into a cytoplasmic extract (supernatant) 
and nuclear pellet.  Cytoplasmic extracts were collected in new 1.5mL eppendorf tubes 
and placed on ice.  Nuclear extracts were obtained from nuclear pellets using RIPA 
buffer and sonication.   
Total protein concentrations from whole cell, nuclear, and cytoplasmic extracts 
were estimated with the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific, 
Waltham, MA).  20µg of total protein from whole cell and cytoplasmic extracts and 60µg 
of total protein from nuclear extracts were separated on polyacrylamide gels (4% 
stacking, 10% separating).  Proteins were transferred to iBlot Nitrocellulose Transfer 
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Stacks (Novex by Life Technologies) using the iBlot system (Invitrogen).  Ponceau Red 
stain (Sigma-Aldrich) was used to verify proper transfer of proteins.  Blots were blocked 
in Fast Western Antibody Diluent (Thermo Fisher Scientific) for two hours and incubated 
overnight with primary AR Antibody (Santa Cruz Biotechnology) at 4°C.  Blots were 
then washed in TBST (Sigma-Aldrich) and incubated with secondary conjugated 
antibody.  For signal development, Clarity Western ECL Substrate (Bio-Rad 
Laboratories, Hercules, CA) was added to blots according to the manufacturer’s 
instructions.  Membranes were then stripped and re-probed for the internal control, β-
actin.  This experiment was performed three separate times with similar results.  Results 
from the final experiment are displayed in Figure 5.  
 
Statistical Methods: 
 
All statistical analysis was performed using Graphpad Prism 6.0 software 
(Graphpad Software, Inc., San Diego, CA).  Statistical tests applied for each experiment 
can be found in the corresponding figure legends.  
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Results 
Effects of PTS on Metastatic PCa Cell Viability 
 
We first tested the effects of PTS on metastatic PCa cell viability.  Androgen-
dependent LNCaP cells were treated with PTS (0-20µM) and/or androgen R1881 (10nM) 
for 24, 48, or 72 hours.  Following treatment, the numbers of viable cells in each 
treatment group were counted as described in the Materials and Methods.  Figure 2A 
shows the time and dose-dependent effects of PTS on LNCaP cell viability.  Significant 
inhibitory effects (p<0.001) were observed for PTS at 10µM after 24 hours and 5µM after 
48 and 72 hours.   
A similar experiment was performed using androgen-independent PC-3 cells.  
These cells were treated with different concentrations of PTS (0-20µM) for 24, 48, or 72 
hours.  Following treatment, the numbers of viable cells in each treatment group were 
counted as described in the Materials and Methods.  Figure 2B shows the time and dose-
dependent effects of PTS on PC-3 cell viability.  In these cells, significant inhibitory 
effects (p<0.001) were observed for PTS at 5µM after 48 and 72 hours.  No significant 
effects were observed for PTS on PC-3 cell viability after 24 hours.  
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Figure 2. Time and dose-dependent effects of PTS on LNCaP and PC-3 cell viability. 
LNCaP cells (A) in Media B were treated with different concentrations of PTS and/or 
10nM R1881. PC-3 cells (B) in Media C were treated with different concentrations of 
PTS alone. Viable cell numbers were counted after 24, 48, and 72-hour treatments and 
the data were expressed as means + SEM of three biologic replicates. Two-way ANOVA 
followed by Tukey test was applied, with intra-group comparisons made to “Androgen 
Control” (2A) or “Control” (2B). * indicates p<0.05; **, p<0.01; ***, p<0.001.  
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 Cell count experiments were performed with PTS and RSV, as described in the 
Materials and Methods.  In Figure 3, dose-response curves and IC50 values were used to 
illustrate and compare the inhibitory effects of the analogues on LNCaP (Fig. 3A) and 
PC-3 (Fig. 3B) cell viability after 72 hours.  This time point was chosen for display 
because PTS and RSV demonstrated the most potent effects on cell viability (in both cell 
lines) after 72 hours.  In Figure 3A, the IC50 value of PTS was <10µM and was 
significantly lower (p<0.001) than the IC50 value of RSV.  In Figure 3B, the IC50 value of 
PTS was <9µM and was significantly lower (p<0.001) than the IC50 value of RSV.  This 
indicates that PTS had more potent inhibitory effects on LNCaP and PC-3 cell viability as 
compared to RSV.   
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Figure 3.  Comparison of PTS and RSV effects on LNCaP and PC-3 cell viability. 
LNCaP cells (A) in Media B were treated with 10nM R1881 and different concentrations 
of PTS or RSV. PC-3 cells (B) in Media C were treated with different concentrations of 
PTS or RSV alone. Viable cell numbers were counted after 72-hour treatments and 
entered into Graphpad software as means + SEM of three biologic replicates. Treatment 
concentrations were log transformed and viable cell numbers were normalized to 
represent percentage of “Androgen Control” (3A) or “Control” (3B). Dose-response 
curves were plotted using a nonlinear regression formula (log (inhibitor) vs. normalized 
response -- variable slope) and IC50 values were generated from this analysis. IC50 values 
for PTS and RSV were significantly different (p<0.001). 
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Effects of PTS on PSA mRNA Levels in Metastatic PCa Cells  
 
 To clarify whether the chemopreventive effects of PTS in metastatic PCa cells 
could be mediated, at least in part, through effects on AR-mediated events, LNCaP cells 
were treated with PTS (0-20µM) and/or androgen R1881 (10nM) for 24 hours.  After 24 
hours, cells were collected and prepared for SYBR qPCR as described in the Materials 
and Methods.  In Figure 4, the effects of PTS on PSA mRNA levels in LNCaP cells are 
shown.  Treatment with PTS resulted in a dose-dependent inhibition of androgen-induced 
PSA mRNA levels in these cells.  Significant inhibitory effects (p<0.01) were observed 
for PTS at 5µM after 24 hours and these results are consistent with an inhibition of AR-
mediated events.  
 
 
Figure 4.  Effects of PTS on androgen-induced PSA mRNA levels in LNCaP cells. 
LNCaP cells in Media B were treated with different concentrations of PTS and/or 10nM 
R1881 for 24 hours. Cells were harvested and total RNA was purified and reverse 
transcribed. Relative quantification (RQ) values for PSA mRNA were determined using 
qPCR as described in the Materials and Methods. Relative PSA mRNA levels were 
expressed as means + SEM of three separate experiments.  One-way ANOVA followed 
by Tukey test was applied, with statistical comparisons made to “Androgen Control.”       
* indicates p<0.05; **, p<0.01; ***, p<0.001.   
!
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Effects of PTS on the AR Protein in Metastatic PCa Cells  
 
To determine if PTS’s inhibition of androgen-induced PSA mRNA levels could 
be attributed to changes in the expression or nuclear translocation of AR protein, LNCaP 
cells were treated with different concentrations of PTS (0-20µM) and/or 10nM R1881 for 
24 hours.  After 24 hours, cells were harvested and a whole cell lysate (Fig. 5A), 
cytoplasmic extract (Fig. 5B), and nuclear extract (Fig. 5C) were obtained.  Proteins were 
separated on polyacrylamide gels and Western blots were performed as described in the 
Materials and Methods.  This experiment was repeated three times with similar results.  
In Figure 5A, we observed that treatment with PTS had no effect on total androgen-
induced AR protein expression at concentrations below 10µM.  In Figures 5B and 5C, we 
observed that treatment of LNCaP cells with PTS did not effect androgen-induced AR 
nuclear translocation.  These results suggest that PTS’s inhibition of androgen-induced 
PSA mRNA levels cannot be fully attributed to effects on AR protein expression or to 
any effects on AR nuclear translocation.   
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Figure 5. Effects of PTS on androgen-induced expression and localization of AR 
protein in LNCaP cells. LNCaP cells in Media B were treated with different 
concentrations of PTS and/or 10nM R1881 for 24 hours. Whole cell (A), cytoplasmic 
(B), and nuclear (C) extracts were obtained and separated on polyacrylamide gels (4% 
stacking, 10% separating). Western blots were performed with anti-AR antibody before 
membranes were stripped and re-probed for β-actin (internal control).  Experiment was 
performed three separate times with similar results.  
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Discussion 
RSV demonstrates unique chemopreventive effects in pre-clinical studies of PCa, 
but low bioavailability renders the compound ineffectual in human subjects [23-25].  
Recently, a structural analogue called PTS was found to possess a superior 
pharmacokinetic profile to RSV while maintaining similar pharmacologic activity 
[9,22,28-30].  However, the chemopreventive activity of PTS in PCa has not been well 
established.  In the current study, we assessed the chemopreventive activity of PTS in 
PCa by investigating its effects on cell viability and AR-mediated events in metastatic 
PCa cells.    
We found that PTS inhibited the viability of both androgen-dependent and 
androgen-independent PCa cells.  These findings are consistent with the results reported 
by Wang and Chakraborty et. al, and serve to validate PTS’s chemopreventive activity in 
metastatic PCa [32,33].  However, the chemopreventive effects of PTS may not be 
limited to advanced disease.  LNCaP cells, while of metastatic lineage, are commonly 
used in research to represent earlier stages of disease.  This is due to the androgen-
dependent status of these cells, as well as their relatively low tumorigenicity in 
comparison to other metastatic PCa cell lines [34].  Thus, while only metastatic PCa cells 
were used in this study, it is important to note that PTS may provide chemopreventive 
effects at multiple stages of disease.  
In addition to validating the general chemopreventive activity of PTS in PCa, our 
cell count experiments also allowed us to compare the effects of PTS to its well-studied 
structural analogue, RSV.  We found that both analogues had time and dose-dependent 
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effects on LNCaP and PC-3 cell viability.  Benitez et. al originally reported that RSV 
produced time and dose-dependent effects on PCa cell viability, but this is the first study 
to demonstrate that PTS works in similar fashion [14].  Both analogues demonstrated the 
most potent inhibitory effects after 72 hours and their respective dose-response curves 
and IC50 values were compared at this time point in Figure 3.  We found that PTS 
inhibited cell viability with greater potency than RSV in both cell lines, demonstrating 
significant inhibitory effects at low micromolar concentrations.  Dose-escalation studies 
involving PTS have yet to be performed in human subjects, but concentrations of 
unchanged RSV have been measured in human serum at ~5µM [25,26].  Extrapolating 
from PTS’s superior bioavailability to RSV in animal models, it is therefore possible that 
the concentrations of PTS used in this study may be attainable in human serum 
[25,29,30].  As a result, PTS may hold greater potential to elicit chemopreventive effects 
in humans than RSV.  
To further clarify how PTS produces chemopreventive effects in metastatic PCa 
cells, we investigated its effects on the AR and AR-mediated events.  The AR plays a 
significant role in the initiation and progression of PCa and this pathway remains the 
primary therapeutic target in the treatment of advanced disease [5].  We also chose to 
investigate the effects of PTS on this signaling pathway because the chemopreventive 
effects of RSV are known to be mediated, at least in part, by an inhibition of AR 
expression and function [15-18].  To assess the effects of PTS on the AR and AR-
mediated events we performed experiments in androgen-dependent LNCaP cells.  
Androgen-dependent cells rely on exogenous androgens for survival and are highly 
sensitive to changes in exogenous androgen levels.  As a result, any effects of PTS on the 
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AR and AR-mediated events can be easily discerned in LNCaP cells.  
Examples of androgen-induced effects on LNCaP cells can be found in the results 
of each experiment.  In Figure 2A, “Androgen Control” groups (0µM PTS, 10nM R1881) 
demonstrated significantly (p<0.001) greater numbers of viable cells than “Control” 
groups (0µM PTS, 0nM R1881) at the 48 and 72 hour time points.  “Androgen Control” 
groups also showed significantly greater (p<0.05) PSA mRNA levels (Fig. 4) and whole 
cell AR protein expression (Fig. 5) as compared to their corresponding “Control” groups 
after 24 hours.  These results are to be expected as AR expression and function are 
enhanced following exposure of LNCaP cells to exogenous androgen supplies [15,16].  
Androgen treatment results in greater cell viability (Fig. 2A) because AR activity plays a 
significant role in the survival and proliferation of PCa cells [33].    
To determine if PTS affects androgen-induced PSA mRNA levels in LNCaP cells 
we performed qPCR experiments.  As shown in Figure 4, PTS inhibited androgen-
induced PSA mRNA levels in a dose-dependent manner and significant inhibitory effects 
were observed for PTS at 5µM after 24 hours.  These effects on the mRNA levels of 
PSA, a well-known ARG, are consistent with an inhibition of AR-mediated events.  As 
previously mentioned, the AR plays a significant role in the initiation and progression of 
PCa and represents the primary therapeutic target in the treatment of advanced disease 
[2,4-6].  Thus, the chemopreventive effects of PTS in metastatic PCa cells may be due, at 
least in part, to effects on AR-mediated events.  
To gain more specific information regarding the effects of PTS on the AR and 
AR-mediated events, we performed Western blot experiments in LNCaP cells.  In Figure 
5, we found that PTS had no effect on androgen-induced AR nuclear translocation.  We 
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also found that total AR protein levels were unaffected by treatment with PTS at 
concentrations up to 10µM (Fig. 5A).  Based on these results, we cannot fully attribute 
the inhibitory effects of PTS on PSA mRNA levels to effects on total AR protein levels 
or to any effects on AR nuclear translocation.  Interestingly, we did observe a decline in 
androgen-induced AR protein expression when cells were treated with PTS at 15-20µM 
(Fig. 5A).  It has previously been reported that RSV triggers degradation of the AR 
protein at high concentrations (~50µM) [15-17].  It is possible that PTS, like RSV, also 
has post-translational effects on the AR protein at high concentrations.  However, this is 
only a hypothesis and effects on androgen-induced AR protein expression do not appear 
to play a significant role in PTS’s inhibition of PSA mRNA levels.  Thus, while PTS 
appears to inhibit AR-mediated events in metastatic PCa cells, the full mechanism(s) 
behind this activity have yet to be fully elucidated. 
Recent advances in the molecular mechanisms of AR function indicate that two 
long non-coding RNAs (lncRNAs), PCGEM1 and PRNCR1, serve as integral 
components of an adaptor complex formed between an AR-bound enhancer site and the 
promoter region of an ARG [35,36].  Furthermore, interactions between these lncRNAs 
and the AR are affected by AR acetylation status, which is partially determined by the 
deacetylase, SIRT1 [36-38].  RSV is a well-established SIRT1 activator [38].  Given the 
structural similarity of PTS to RSV, as well as the mounting evidence of its similar 
pharmacologic activity, we speculate that PTS may also serve as a SIRT1 activator.  
Therefore, we postulate that PTS may inhibit AR transcriptional activity by activating 
SIRT1, enhancing AR deacetylation, and inhibiting the interaction of lncRNAs and the 
AR.  This could inhibit the formation of adaptor complexes utilized by wild-type and 
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ligand-independent ARs to facilitate the transcription of ARGs [36].  In summary, 
PCGEM1 and PRNCR1 may represent new therapeutic targets in advanced PCa and it 
would be interesting to investigate whether any correlation exists between PTS’s 
inhibitory effects on AR-mediated events and the expression and/or function of these 
lncRNAs.  
We have so far highlighted the observed and potential effects of PTS on the AR 
and AR-mediated events in androgen-dependent LNCaP cells, but it should also be noted 
that PTS demonstrated chemopreventive activity in PC-3 cells.  PC-3 cells are androgen-
independent cells that are insensitive to changes in exogenous androgen supplies and are 
capable of survival in androgen-depleted environments [39].  While results from recent 
studies indicate that these cells also express the AR, they do so at much lower levels and 
demonstrate significantly less AR-mediated activity than LNCaP cells [39].  Thus, AR 
signaling may play a far less prominent role in cell survival and proliferation in these 
cells as compared to LNCaP cells.  In our cell count experiments, we found that PTS 
inhibited the viability of LNCaP and PC-3 cells with very similar potency.  These results 
suggest that the chemopreventive effects of PTS are not entirely mediated through effects 
on the AR.  This further supports the hypothesis that PTS acts in similar fashion to RSV, 
which demonstrates a number of AR-independent effects in PCa [27].  The AR-
independent effects of PTS should also be investigated further as they will likely improve 
our understanding of PTS’s pharmacologic activity in PCa, and may also implicate PTS 
as a potential chemopreventive agent in other cancers.   
In conclusion, PTS demonstrates potent chemopreventive effects in both 
androgen-dependent and androgen-independent metastatic PCa cells.  We believe that 
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these effects are mediated, at least in part, through an inhibition of AR signaling.  PTS 
does not inhibit AR signaling by affecting AR nuclear translocation and the mechanism 
behind this inhibition has yet to be fully elucidated.  Future investigation may reveal that 
PTS modulates AR activity like its structural analogue RSV.  This would mean that the 
chemopreventive effects of PTS are at least partially mediated through a mechanism of 
action that is unique to any current ADT agent.  A better understanding of this 
mechanism could provide insight into new therapeutic targets in the AR signaling 
pathway.  In closing, PTS should be investigated further to better elucidate its 
chemopreventive effects in PCa cells and to assess its potential for clinical applicability 
in PCa. 
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